Clinical Research Directory

Inclusion Criteria: * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2 * NOTE: Patients with a history of metastatic cancer or an ECOG performance status of 2 must have laboratory (lab) work completed =\< 28 days prior to registration * Pain, numbness, tingling or other symptoms of CIPN of \>= 3 months (90 days) duration for which the patient is seeking an intervention * Neurotoxic chemotherapy must have been completed \>= 3 months (90 days) prior to registration and there must be no further planned neurotoxic -chemotherapy for \> 2 months after registration Note: The study is limited to those with taxane- and/or platinum-based neuropathy * Patient must note tingling, numbness or pain symptoms of at least a four out of ten =\< 7 days prior to registration. * Note: On a 0-10 scale where zero was 'no problem' and ten being 'as bad a problem that could be imagined': how much of a problem has numbness, tingling, and/or pain in your fingers and/or toes been in the past week? * Patient must be able to speak, read and comprehend English * For women of childbearing potential only, a negative urine or serum pregnancy test done =\< 14 days prior to registration is required * A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months) * NOTE: If the urine test cannot be confirmed as negative, a serum pregnancy test will be required * Life expectancy \>= 6 months * Platelet count \> 100,000/mm\^3 * NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =\< 28 days prior to registration * Absolute neutrophil count (ANC) \>= 1,000/mm\^3 * NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =\< 28 days prior to registration * Hemoglobin \> 11 g/dL * NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =\< 28 days prior to registration * Serum transaminase (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]) =\< 1.2 x upper limit of normal (ULN) * NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have these labs completed =\< 28 days prior to registration * Alkaline phosphatase =\< 1.2 x ULN * NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =\< 28 days prior to registration * Serum creatinine =\< 1.2 x ULN * NOTE: Patients with a history of metastatic cancer or an ECOG performance status of 2 must have this lab completed =\< 28 days prior to registration * Able to swallow oral medication * Provide written informed consent =\< 28 days prior to registration Exclusion Criteria: * Currently receiving neurotoxic chemotherapy for a second cancer or recurrence of the primary cancer * Impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) * Evidence of residual cancer, per routine clinical practice-based parameters * Comorbid conditions: * Previous diagnosis of diabetic or another non chemotherapy induced peripheral neuropathy * Previous history of peripheral neuropathy prior to receiving neurotoxic chemotherapy * Neuropathy from human immunodeficiency virus (HIV) infection. Note: Patients with HIV infections are eligible as long as they do not have a neuropathy from their viral illness * Concurrent use of a cannabis product (tetrahydrocannabinol \[THC\] and/or cannabidiol \[CBD\]). Patients should have discontinued these products \>= 4 weeks prior to registration * Current or previous use of PEA * Currently receiving or planning to start any of the following agents: opioids, duloxetine, gabapentin or pregabalin. Patients are eligible if they discontinue these medications \>= 1 week prior to registration * Any of the following because the study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown: * Pregnant persons * Nursing persons * Persons of childbearing potential who are unwilling to employ adequate contraception